Radius Health, Inc: Mitchell Blutt’s Consonance Capital Management Lp Bought Stake

February 15, 2018 - By Adrian Erickson

 Radius Health, Inc: Mitchell Blutt's Consonance Capital Management Lp Bought Stake

Investors sentiment decreased to 1.37 in Q3 2017. Its down 0.05, from 1.42 in 2017Q2. It turned negative, as 27 investors sold Radius Health, Inc. shares while 25 reduced holdings. 22 funds opened positions while 49 raised stakes. 52.25 million shares or 10.87% more from 47.13 million shares in 2017Q2 were reported.

1,647 were reported by Exane Derivatives. X Management Co Limited Co has 0% invested in Radius Health, Inc. (NASDAQ:RDUS) for 497 shares. Schwab Charles Invest Mgmt has 0.01% invested in Radius Health, Inc. (NASDAQ:RDUS) for 180,901 shares. Nationwide Fund reported 0% stake. The New York-based Comml Bank Of New York Mellon has invested 0.01% in Radius Health, Inc. (NASDAQ:RDUS). Citadel Advisors reported 1.25M shares stake. 1.61M are held by Timessquare Management Ltd Liability Corp. Bb Biotech Ag holds 5.87% or 5.50M shares in its portfolio. Swiss Natl Bank invested in 0% or 54,000 shares. Cubist Systematic Strategies Limited Liability Corporation has 0.01% invested in Radius Health, Inc. (NASDAQ:RDUS). Financial Bank Of Montreal Can has 0% invested in Radius Health, Inc. (NASDAQ:RDUS) for 31,421 shares. 7,500 were reported by Salzhauer Michael. Millennium Ltd Limited Liability Company stated it has 0.03% of its portfolio in Radius Health, Inc. (NASDAQ:RDUS). Blackrock Inc holds 3.00 million shares. Glenmede Tru Company Na reported 1,100 shares.

Since August 16, 2017, it had 4 insider buys, and 0 selling transactions for $10.17 million activity.

The New Mitchell Blutt’s Consonance Capital Management Lp Holding in Radius Health, Inc

Consonance Capital Management Lp reported SC 13G form with the SEC for Radius Health, Inc. Access it here: 000108514618000828. As reported by Mitchell Blutt’s Consonance Capital Management Lp, the filler owns 5.94% or 2,649,285 shares of the Health Care–company.

Radius Health, Inc stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Mitchell Blutt’s Consonance Capital Management Lp’s positive view for Radius Health, Inc. For a hedge fund managing $513.80 million in assets and having 8+ experts this is interesting position.

The hedge fund is investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Mitchell Blutt’s Consonance Capital Management Lp’s portfolio is in the sector.

Radius Health, Inc Institutional Sentiment

Filings show 118 investors own Radius Health, Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 3898009. 33494291 were owned by these investors. 25 funds opened new Radius Health, Inc stakes, 68 increased positions. There were 21 that closed positions and 23 reduced them.

4 investors had the stock in their top 10. Some are: Mpm Asset Management Llc, Bb Biotech Ag..

Green Owl Capital Management Llc is an investor bullish on Radius Health, Inc, owning 30000 shares as of Q3 2015 for 1.61% of its portfolio. Bain Capital Brookside Capital Management Llc owns 2018971 shares or 4.17% of its portfolio. V8 Bb Biotech Ag have 9.39% of its portfolio for 4272140 shares. Further, Rock Springs Capital Management Lp reported stake worth 3.15% of its portfolio. The MA Mpm Asset Management Llc owns 5831253 shares. Radius Health, Inc is 62.17% of its portfolio.

Business Profile

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.

SEC Form 13G.

Mitchell Blutt’s Consonance Capital Management Lp website.

Analysts await Radius Health, Inc. (NASDAQ:RDUS) to report earnings on February, 22. They expect $-1.49 EPS, down 22.13 % or $0.27 from last year’s $-1.22 per share. After $-1.31 actual EPS reported by Radius Health, Inc. for the previous quarter, Wall Street now forecasts 13.74 % negative EPS growth.

The stock increased 0.41% or $0.16 during the last trading session, reaching $38.79. About 524,005 shares traded. Radius Health, Inc. (NASDAQ:RDUS) has risen 9.02% since February 15, 2017 and is uptrending. It has underperformed by 7.68% the S&P500.

Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. The company has market cap of $1.73 billion. The Company’s product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. It currently has negative earnings. The firm is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer.

Radius Health, Inc. (NASDAQ:RDUS) Ratings Coverage

Among 11 analysts covering Radius Health (NASDAQ:RDUS), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Radius Health has $90 highest and $30.0 lowest target. $57.20’s average target is 47.46% above currents $38.79 stock price. Radius Health had 29 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Hold” rating by Jefferies on Monday, June 5. As per Monday, September 25, the company rating was maintained by Cantor Fitzgerald. The rating was initiated by H.C. Wainwright with “Buy” on Monday, May 23. The firm has “Neutral” rating given on Wednesday, March 30 by Goldman Sachs. As per Thursday, August 3, the company rating was maintained by Jefferies. Canaccord Genuity maintained Radius Health, Inc. (NASDAQ:RDUS) on Monday, June 5 with “Buy” rating. The firm has “Hold” rating given on Tuesday, October 10 by Jefferies. H.C. Wainwright maintained Radius Health, Inc. (NASDAQ:RDUS) rating on Friday, March 24. H.C. Wainwright has “Buy” rating and $66 target. The firm has “Hold” rating by Citigroup given on Wednesday, December 6. The stock has “Outperform” rating by Cowen & Co on Friday, May 6.

More notable recent Radius Health, Inc. (NASDAQ:RDUS) news were published by: Seekingalpha.com which released: “Radius Health: Updates To Thesis” on January 30, 2018, also Benzinga.com with their article: “Analyst: Radius Health Could Advance 50% With Osteoporosis Treatment, Breast …” published on January 29, 2018, Globenewswire.com published: “Radius Health to Present at 2018 RBC Capital Markets Global Healthcare Conference” on February 14, 2018. More interesting news about Radius Health, Inc. (NASDAQ:RDUS) were released by: Globenewswire.com and their article: “Radius Health to Present at Leerink Partners 7th Annual Global Healthcare …” published on February 08, 2018 as well as Prnewswire.com‘s news article titled: “This Morning’s Technical Outlook on Biotech Stocks — Portola Pharma, Protalix …” with publication date: February 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.